Evidence map›Paper›PMID 34021247›Full record

ArticleLeukemia2021

Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.

Caner Saygin, Eileen Hu, Pu Zhang, Steven Sher, Arletta Lozanski, Tzyy-Jye Doong, Deedra Nicolet, Shelley Orwick, Jadwiga Labanowska, Jordan N Skinner and 17 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 1 country.

Caner SayginDepartment of Internal Medicine, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-7617-8356
Eileen HuDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Pu ZhangDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Steven SherDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Arletta LozanskiDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Tzyy-Jye DoongDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Deedra NicoletAlliance Statistics and Data Center, The Ohio State University, Columbus, OH, USA.
Shelley OrwickDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Jadwiga LabanowskaDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Jordan N SkinnerDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Casey CempreDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Tierney KauffmanDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Virginia M GoettlDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Nyla A HeeremaDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Lynne AbruzzoDepartment of Pathology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-6113-7447
Cecelia MillerDepartment of Pathology, The Ohio State University, Columbus, OH, USA.
Rosa LapalombellaDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Gregory BehbehaniDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Alice S MimsDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-8971-2199
Karilyn LarkinDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Nicole GrieselhuberDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Alison WalkerDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Bhavana BhatnagarDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Clara D BloomfieldDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-5465-7591
John C ByrdDivision of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Gerard Lozanski *Department of Pathology, The Ohio State University, Columbus, OH, USA.
James S Blachly *Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. James.Blachly@osumc.edu.ORCID http://orcid.org/0000-0002-4275-5562
The Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
Targeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6M
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M
A Paradigm Shift in Chronic Lymphocytic Leukemia: Defining the Role of Hematopoietic Stem Cells in LeukemogenesisF30CA225070 · NCI · OHIO STATE UNIVERSITY · PI HU, EILEEN YIFAN · 2018 to 2021
$140k
NCI NIH HHS F30 CA225070NCI NIH HHS P30 CA016058NCI NIH HHS R35 CA197734NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338
6 · The paper itself

Abstract

Hematopoiesis is hierarchical, and it has been postulated that acute myeloid leukemia (AML) is organized similarly with leukemia stem cells (LSCs) residing at the apex. Limited cells acquired by fluorescence activated cell sorting in tandem with targeted amplicon-based sequencing (LC-FACSeq) enables identification of mutations in small subpopulations of cells, such as LSCs. Leveraging this, we studied clonal compositions of immunophenotypically-defined compartments in AML through genomic and functional analyses at diagnosis, remission and relapse in 88 AML patients. Mutations involving DNA methylation pathways, transcription factors and spliceosomal machinery did not differ across compartments, while signaling pathway mutations were less frequent in putative LSCs. We also provide insights into TP53-mutated AML by demonstrating stepwise acquisition of mutations beginning from the preleukemic hematopoietic stem cell stage. In 10 analyzed cases, acquisition of additional mutations and del(17p) led to genetic and functional heterogeneity within the LSC pool with subclones harboring varying degrees of clonogenic potential. Finally, we use LC-FACSeq to track clonal evolution in serial samples, which can also be a powerful tool to direct targeted therapy against measurable residual disease. Therefore, studying clinically significant small subpopulations of cells can improve our understanding of AML biology and offers advantages over bulk sequencing to monitor the evolution of disease.

Indexed as

Clonal EvolutionMutationAdultAgedAged, 80 and overBiomarkers, TumorFemaleFlow CytometryFollow-Up StudiesGenomicsHematopoietic Stem CellsHumansImmunophenotypingLeukemia, Myeloid, AcuteMaleMiddle AgedBiomarkers, Tumor

Identifiers

PMID34021247
PMCPMC8606012
OpenAlexW3161453313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.